Table 1 Comparison of clinicopathological characteristics between females and males before and after propensity score matching.
Before matching | After matching | |||||
|---|---|---|---|---|---|---|
Female (n = 4420) | Male (n = 1146) | p-value | Female (n = 1040) | Male (n = 1040) | p-value | |
Age (years) | 46.8 ± 12.2 (range, 12–88) | 45.8 ± 11.8 (range, 11–81) | 0.017 | 46.5 ± 12.4 (range, 14–79) | 46.2 ± 11.8 (range, 11–81) | 0.535 |
Extent of operation | 0.001 | 0.376 | ||||
Less than TT | 3313 (75.0%) | 805 (70.2%) | 764 (73.5%) | 745 (71.6%) | ||
TT and/or mRND | 1107 (25.0%) | 341 (29.8%) | 276 (26.5%) | 295 (28.4%) | ||
Type of carcinoma | 0.823 | 0.986 | ||||
PTC | 4333 (98.0%) | 1124 (98.1%) | 1018 (97.9%) | 1019 (98.0%) | ||
FTC | 75 (1.7%) | 18 (1.6%) | 18 (1.7%) | 17 (1.6%) | ||
HTC | 12 (0.3%) | 4 (0.3%) | 4 (0.4%) | 4 (0.4%) | ||
Tumor size (cm) | 0.9 ± 0.7 (range, 0.2–9.0) | 1.1 ± 0.8 (range, 0.2–5.5) | < 0.001 | 1.1 ± 0.8 (range, 0.2–6.5) | 1.1 ± 0.8 (range, 0.2–5.5) | 0.933 |
ETE | 250 (5.7%) | 45 (3.9%) | 0.022 | 39 (3.8%) | 40 (3.8%) | 0.909 |
Multifocality | 1708 (38.6%) | 446 (38.9%) | 0.865 | 398 (38.3%) | 390 (37.5%) | 0.752 |
Bilaterality | 414 (9.4%) | 101 (8.8%) | 0.607 | 101 (9.7%) | 82 (7.9%) | 0.163 |
Lymphatic invasion | 1086 (24.6%) | 393 (34.3%) | < 0.001 | 326 (31.3%) | 325 (31.3%) | 0.962 |
Vascular invasion | 83 (1.9%) | 46 (4.0%) | < 0.001 | 35 (3.4%) | 35 (3.4%) | 1.000 |
Perineural invasion | 81 (1.8%) | 24 (2.1%) | 0.544 | 21 (2.0%) | 20 (1.9%) | 0.875 |
BRAFV600E positive | 2871/3650 (78.7%) | 748/929 (80.5%) | 0.223 | 659/866 (76.1%) | 675/846 (79.8%) | 0.071 |
Harvested LNs | 10.7 ± 12.1 | 12.6 ± 16.7 | < 0.001 | 10.8 ± 12.3 | 11.7 ± 15.2 | 0.109 |
Positive LNs | 1.7 ± 3.4 | 3.1 ± 4.9 | < 0.001 | 2.4 ± 3.8 | 2.6 ± 3.9 | 0.355 |
T stage | 0.710 | 0.779 | ||||
T1 | 3911 (88.5%) | 991 (86.5%) | 924 (88.8%) | 909 (87.4%) | ||
T2 | 218 (4.9%) | 91 (7.9%) | 64 (6.2%) | 74 (7.1%) | ||
T3a | 41 (0.5%) | 19 (1.7%) | 13 (1.3%) | 17 (1.6%) | ||
T3b | 238 (5.4%) | 44 (3.8%) | 37 (3.6%) | 39 (3.8%) | ||
T4a | 12 (0.3%) | 1 (0.1%) | 2 (0.2%) | 1 (0.1%) | ||
N stage | < 0.001 | 0.502 | ||||
N0 | 2351 (53.2%) | 471 (41.1%) | 456 (43.8%) | 455 (43.8%) | ||
N1a | 1880 (42.5%) | 597 (52.1%) | 533 (51.3%) | 522 (50.2%) | ||
N1b | 189 (4.3%) | 78 (6.8%) | 51 (4.9%) | 63 (6.1%) | ||
M stage | 0.471 | |||||
M1 | 2 (0.0%) | 0 (0.0%) | 0 (0%) | 0 (0%) | ||
TNM stage | 0.021 | 0.530 | ||||
Stage I | 3903 (88.3%) | 983 (85.8%) | 887 (85.3%) | 898 (86.3%) | ||
Stage II | 516 (11.7%) | 163 (14.2%) | 153 (14.7%) | 142 (13.7%) | ||
Stage III | 1 (0.0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0.530 | |
Recurrence | 96 (2.2%) | 38 (3.3%) | 0.030 | 26 (2.5%) | 31 (3.0%) | 0.591 |
